Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)

被引：0
|
作者：
Quach, Hang [1 ]
Prince, Miles H. [1 ]
Mileshkin, Linda [1 ]
Seymour, John F. [1 ]
Westerman, David [1 ,2 ]
Milner, Alvin D. [3 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2718.2718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2718
引用
收藏
页码：798A / 798A
页数：1
相关论文
共 50 条
  • [31] Combination Therapy with Isatuximab in relapsed multiple Myeloma Superior progression-free Survival and clinically meaningful Depth of Response
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [32] Impact on Response and Survival of DNA Repair Single Nucleotide Polymorphisms In Relapsed or Refractory Multiple Myeloma Patients Treated with Thalidomide.
    Fernandez de Larrea, Carlos
    Teresa Cibeira, Maria
    Navarro, Alfons
    Diaz, Tania
    Fuster, Dolors
    Tovar, Natalia
    Rosinol, Laura
    Monzo, Mariano
    Blade, Joan
    BLOOD, 2010, 116 (21) : 1647 - 1648
  • [33] RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Betts, K.
    Chen, C.
    Zichlin, M.
    Brun, A.
    Signorovitch, J.
    Makenbaeva, D.
    HAEMATOLOGICA, 2017, 102 : 533 - 533
  • [34] Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S334 - S335
  • [35] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [36] USING LIVESLR PLATFORMTO EVALUATE THE IMPACT OF DURATION OF TREATMENT (DOT) ON PROGRESSION FREE SURVIVAL (PFS) IN MULTIPLE MYELOMA (MM)
    He, C.
    Ammann, E.
    Forsythe, A.
    VALUE IN HEALTH, 2022, 25 (12) : S45 - S45
  • [37] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    Prince, H. M.
    Schenkel, B.
    Mileshkin, L.
    LEUKEMIA, 2007, 21 (04) : 818 - 820
  • [38] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    H M Prince
    B Schenkel
    L Mileshkin
    Leukemia, 2007, 21 : 818 - 820
  • [39] Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients.
    Grosbois, B
    Bellissant, E
    Moreau, P
    Attal, M
    Zerbib, R
    BLOOD, 2001, 98 (11) : 163A - 163A
  • [40] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
12345